Article Dans Une Revue Targeted Oncology Année : 2025

Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study

Florian Guisier
  • Fonction : Auteur

Résumé

Background ROS1 chromosomic rearrangement is a rare oncogenic driver, and patients with this rearrangement benefit from specific targeted treatments in the first-line setting. However, therapeutic options are limited in pretreated patients. Brigatinib is a validated drug for ALK rearrangements, and also has an in vitro activity against ROS1. In vivo efficacy is also suggested in some clinical series. Objective We aimed to specifically study brigatinib in patients with pretreated advanced non-small-cell lung cancer (NSCLC). Methods We retrospectively collected data from 20 centers in France. Brigatinib was delivered through a compassionate use program in France between 2018 and 2020. The primary endpoint was progression-free survival. Secondary endpoints were the objective response rate, overall survival, and tolerance. Results Twenty-five patients treated with brigatinib were included in our study. All patients were pretreated, and all of them previously received crizotinib. Median progression-free survival was 3.8 months (95% confidence interval 2.8-7.1). The objective response rate was 32%, with a disease control rate of 48%. Three patients had a prolonged response of more than 18 months at the end of data collection. We did not identify factors predictive of prolonged response. There were no grade 4 or 5 toxicities. Conclusion Brigatinib may represent an interesting therapeutic option for patients who have progressed after standard treatments.

Fichier principal
Vignette du fichier
Target Oncol 2025.pdf (1.7 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Licence

Dates et versions

inserm-05216731 , version 1 (20-08-2025)

Licence

Identifiants

Citer

Jean Mourlanette, Gaelle Rousseau-Bussac, Siham Mallah, Florian Guisier, Gerard Zalcman, et al.. Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study. Targeted Oncology, 2025, 20 (2), pp.311-317. ⟨10.1007/s11523-025-01131-x⟩. ⟨inserm-05216731⟩
386 Consultations
35 Téléchargements

Altmetric

Partager

  • More